Ocugen Inc
Closed
1.39
Overview
Share price change
24h
Min
1.37
Max
1.41
Income | -5.7M -25M |
|---|---|
Sales | -45K 1.5M |
EPS | -0.07 |
Profit margin | -1,671.841 |
Employees | 116 |
EBITDA | -2.5M -20M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +637.41% upside |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 41M 458M |
|---|---|
Previous open | 1.39 |
Previous close | 1.39 |
Ocugen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ocugen Inc Forecast
Price Target
By TipRanks
637.41% upside
12 Months Forecast
Average 10.25 USD 637.41%
High 12 USD
Low 8 USD
Based on 4 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
